6'-Methylepibatidine

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 地棘蛙素类似物
• 英文名称: 6'-Methylepibatidine
• 英文别名: 2-(6-chloro-2-methylpyridin-3-yl)-7-azabicyclo[2.2.1]heptane
• 化学式: C₁₂H₁₅ClN₂
• 分子量: 222.71
• InChiKey: CEIOZCMVGWULLM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
  申请人：Pfizer Inc.

  公开号：US20030134844A1

  公开（公告）日：2003-07-17

  This invention relates to the use of nicotinic acetylcholine receptor agonists for the treatment of restless legs syndrome (RLS). The invention further relates to the use of a nicotinic acetylcholine receptor agonist in the manufacture of a medicament for the treatment of RLS. The present invention also relates to a pharmaceutical composition for the treatment of RLS containing a nicotinic acetylcholine receptor agonist.

  这项发明涉及尼古丁型乙酰胆碱受体激动剂用于治疗不安腿综合征（RLS）。该发明还涉及尼古丁型乙酰胆碱受体激动剂在制造治疗RLS药物中的应用。本发明还涉及一种含有尼古丁型乙酰胆碱受体激动剂的治疗RLS的药物组合物。
• 7-hetero-bicyclo[2.2.1]-heptanes
  申请人：——

  公开号：US20020035262A1

  公开（公告）日：2002-03-21

  Compounds of the formula 1 and their pharmaceutically acceptable salts, wherein R 1 , R 2 , R 3 and R 4 are defined as in the specification, intermediates in the synthesis of such compounds, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of neurological and psychological disorders are claimed.

  本发明声明的化合物公式1及其药学上可接受的盐，其中R1、R2、R3和R4如规范中定义，用于合成这种化合物的中间体，含有这种化合物的制药组合物以及使用这种化合物治疗神经和心理障碍的方法。
• 7-Hetero-bicyclo[2.2.1]-heptanes
  申请人：——

  公开号：US20020038028A1

  公开（公告）日：2002-03-28

  Compounds of the formula 1 and their pharmaceutically acceptable salts, wherein R 1 , R 2 , R 3 and R 4 are defined as in the specification, intermediates in the synthesis of such compounds, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of neurological and psychological disorders are claimed.

  本发明涉及化合物1及其药学上可接受的盐，其中R1、R2、R3和R4如规范中定义，以及合成这些化合物的中间体，含有这些化合物的药物组合物和使用这些化合物治疗神经和心理障碍的方法。
• 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylchloline receptors
  申请人：Pfizer Products Inc.

  公开号：EP0955301A2

  公开（公告）日：1999-11-10

  Compounds of the formula and their pharmaceutically acceptable salts, wherein R1, R2, R3 and R4 are defined as in the specification, intermediates in the synthesis of such compounds, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of neurological and psychological disorders are claimed.

  式中 R1、R2、R3 和 R4 的化合物及其药学上可接受的盐 以及它们的药学上可接受的盐类（其中 R1、R2、R3 和 R4 的定义如说明书中所述）、合成此类化合物的中间体、含有此类化合物的药物组合物和使用此类化合物治疗神经和心理疾病的方法。
• Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
  申请人：Saltarelli D. Mario

  公开号：US20050250806A1

  公开（公告）日：2005-11-10

  This invention relates to the use of nicotinic acetylcholine receptor agonists for the treatment of restless legs syndrome (RLS). The invention further relates to the use of a nicotinic acetylcholine receptor agonist in the manufacture of a medicament for the treatment of RLS. The present invention also relates to a pharmaceutical composition for the treatment of RLS containing a nicotinic acetylcholine receptor agonist.

  本发明涉及使用烟碱乙酰胆碱受体激动剂治疗不宁腿综合征（RLS）。本发明还涉及使用烟碱乙酰胆碱受体激动剂制造治疗 RLS 的药物。本发明还涉及一种含有烟碱乙酰胆碱受体激动剂的治疗 RLS 的药物组合物。